title: [Studies on the mechanism of Polyactin A's enhancive effect on NK cell activity].
abstract: It has been shown that the novel immunopotentiator Polyactin A (PAA) developed in China can augment NK cell activity. In order to further understand the mechanism of PAA effect on NK activities, we measured the binding and lytic capacities of peripheral blood lymphocytes (PBL) isolated from normal subjects and patients with esophageal carcinoma against K562 target cells by using a single cell cytotoxicity assay. Morphologically the ultrastructures of NK cells of normal subjects and the patients on PAA were also studied. The results showed that: (1) Preincubation PBL of normal subjects on PAA at 100 micrograms/ml for 4 hours could increase the rate of NK lysis with no effect on the binding rate. The binding capacities of PBL of patients with esophageal carcinoma were lower than those of normal subjects. Pretreatment PBL of patients with esophageal carcinoma could significantly increase not only the rate of NK lysis, but also the binding rate. (2) Study on the processes of conjugation and cytolysis by using light microscopic morphology, scanning electron microscopy (SEM) and transmission electron microscopy (TEM) found that effector cells include not only large granular lymphocytes (LGL), but also non-LGL bound to target cells. One effector cell could simultaneously make contacts with more than one target cell. It was found that PBL/K562 contacts could be morphologically divided into two types in the SEM and TEM. Either effector cell protrusions were pushed deep into pouches and lacunae of the target cell surface or a wide area of intimate cell-to-cell contact was formed. Effector/target cell contact is a prerequisite for NK lytic activity.(ABSTRACT TRUNCATED AT 250 WORDS)
authors: Department of Pharmacology, Chinese Academy of Medical Sciences.
authors: W
authors: W
authors: Qiang
authors: Y
authors: Y
authors: Wang
authors: Y
authors: Y
authors: Lei
authors: J
authors: J
authors: Liu
mesh_terms: D000328:Adult; D003602:Cytotoxicity, Immunologic; D004938:Esophageal Neoplasms / Q000473:pathology; D006020:Glycopeptides / Q000494:pharmacology*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000276:immunology*; D008214:Lymphocytes / Q000276:immunology; D008875:Middle Aged
chemical_list: D006020:Glycopeptides; D007155:Immunologic Factors; C064233:polyactin A